From conventional to stealth liposomes a new frontier in cancer chemotherapy

Tumori

Volumn 89, Issue 3, 2003, Pages 237-249

  Cattel, Luigi ^a   Ceruti, Maurizio ^a   Dosio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Daunorubicin; Doxorubicin; Liposomes; Stealth liposomes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; GANGLIOSIDE; LIPOSOME; MACROGOL; PHOSPHOLIPID DERIVATIVE; PK 1; PLASMID VECTOR; RADIOISOTOPE; SIALIC ACID; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DNA VECTOR; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; GENE THERAPY; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIDE EFFECT; VOMITING;

EID: 0041426521     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900302     Document Type: Review

References (121)

1. Langer R: Drug delivery and targeting. Nature, 392: 5-10, 1998.
2. Torchilin VP: Drug targeting. Eur J Pharm Sci, 11: S81-91, 2000.
3. Cattel L, Dosio F, Brusa P, Arpicco S: The role of conjugation processes and linking agents in the preparation of molecular/particulate conjugates. A review. STP Pharma Sci, 9: 307-319, 1999.
4. Monfardini C, Veronese FM: Stabilization of substances in circulation. Bioconjug Chem, 9: 418-450, 1998.
5. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R: HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer, 35: 994-1002, 1999.
6. Frankel AE, Kreitman RJ, Sausville EA: Targeted toxins. Clin Cancer Res, 6: 326-334, 2000.
7. Canevari S, Colnaghi MI, Cattel L, Dosio F: Antibody-toxin conjugates. Chemistry of coupling and purification. In: Cancer drug discovery and development: tumor targeting in cancer therapy, Pagé M (Ed), pp 289-305, Humana Press Inc, Totowa, NJ, 2002.
8. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res, 5: 83-94, 1999.
9. Sharma A, Sharma US: Liposomes in drug delivery: progress and limitations. Int J Pharm, 154: 123-140, 1997.
10. Lundberg B: Cytotoxic activity of two new lipophilic steroid nitrogen carbamates incorporated into low-density lipoprotein. Anticancer Drug Des, 9: 471-476, 1994.
11. Kwon GS, Kataoka K: Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev, 16: 295-309, 1995.
12. Jeong B, Bae YH, Lee DS, Kim SW: Biodegradable block copolymers as injectable drug-delivery systems. Nature, 388: 860-862, 1997.
13. Bangham AD: Development of the liposome concept. In: Liposomes in biological systems, Gregoriadis G, Allison AC (Eds), chapter 1, John Wiley & Sons, Chichester, 1980.
14. Gregoriadis G: Targeting of drugs. Nature, 265: 407-411, 1977.
15. Poste G: Liposome targeting in vivo: problems and opportunities. Biol Cell, 47: 19-37, 1983.
16. Gregoriadis G, Neerunjun ED: Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. Eur J Biochem, 47: 179-185, 1974.
17. Scherphof GL, Dijkstra J, Spanjer HH, Derksen JTP, Roerdink FH: Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann NY Acad Sci, 446: 368-384, 1985.
18. Harashima H, Kiwada H: Liposomal targeting and drug delivery: kinetic consideration. Adv Drug Deliv Rev, 19: 425-444, 1996.
19. Du Plessis J, Ramachandran C, Weiner N, Müller DG: The influence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage. Int J Pharm, 127: 273-278, 1996.
20. Lasic DD: Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J Contr Release, 48: 203-222, 1997.
21. Juliano RL: Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv Drug Deliv Rev, 2: 31-54, 1988.
22. Meunier F, Prentice HG, Ringdén O: Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother, 28, Suppl B: 83-91, 1991.
23. Tardi PG, Boman NL, Cullis PR: Liposomal doxorubicin. J Drug Target, 4: 129-140, 1996.
24. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol, 17: 1435-1441, 1999.
25. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol, 17: 1425-1434, 1999.
26. Swenson CE, Perkins WR, Roberts P, Janoff AS: Liposome technology and the development of MyocetTM (liposomal doxorubicin citrate). Breast. 10 (suppl 2): 1-7, 2001.
27. Verrill M: Anthracyclines in breast cancer: therapy and issues of toxicity. Breast, 10 (suppl 2): 8-15, 2001.
28. Batist G: Improving the therapeutic index when using MyocetTM in the treatment of metastatic breast cancer. Breast, 10 (suppl 2): 16-21, 2001.
29. Schmid P, Possinger K: Liposomal anthracyclines for improved cardiac tolerability. Breast, 10 (suppl 2): 22-27, 2001.
30. Marty M: Liposomal doxorubicin (MyocetTM) and conventional anthracyclines: a comparison. Breast, 10 (suppl 2): 28-33, 2001.
31. Federico M, Pronzato P, Amadori D: TLC D-99 (doxorubicina citrato in liposoma non pegilato). In: Therapy perspectives, Adis International, pp 1-52, 2001.
32. Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R, Petrelli N: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res, 53: 2796-2802, 1993.
33. Maeda H, Seymour LW, Miyamoto Y: Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem, 3: 351-362, 1992.
34. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res, 50: 814S-819S, 1990.
35. Gabizon AA: Liposomal anthracyclines. Hematol Oncol Clin North Am, 8: 431-450, 1994.
36. Bonte F, Juliano RL: Interactions of liposomes with serum proteins. Chem Phys Lipids, 40: 359-372, 1986.
37. Schreier H, Abra RM, Kaplan JE, Hunt CA: Murine plasma fibronectin depletion after intravenous injection of liposomes. Int J Pharm, 37: 233-238, 1987.
38. Chonn A, Semple SC, Cullis PR: Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem, 267: 18759-18765, 1992.
39. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR: Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta, 1191: 43-51, 1994.
40. Senior JH: Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst, 3: 123-193, 1987.
41. Chow DD, Essien HE, Padki MM, Hwang KJ: Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther, 248: 506-513, 1989.
42. Senior J, Crawley JCW, Gregoriadis G: Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim Biophys Acta, 839: 1-8, 1985.
43. Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Baccarani M: Liposome-encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP-related multidrug resistance. Haematologica, 84: 1151-1152, 1999.
44. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen EA, Ross ME, Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol, 13: 996-1003, 1995.
45. Forssen EA, Ross ME: Daunoxomer treatment of solid tumors: preclinical and clinical investigations. J Liposome Res, 4: 481-512, 1994.
46. Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S, Tromberg BJ: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res, 56: 2066-2075, 1996.
47. Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Michelutti T, Russo D, Pea F, Baccarani M: Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol, 106: 92-99, 1999.
48. Gabizon A, Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85: 6949-6953, 1988.
49. Allen TM, Hansen C, Rutledge J: Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta, 981: 27-35, 1989.
50. Namba Y, Sakakibara T, Masada M, Ito F, Oku N: Glucuronate-modified liposomes with prolonged circulation time. Chem Pharm Bull, 38: 1663-1666, 1990.
51. Oku N, Namba Y, Okada S: Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta, 1126: 255-260, 1992.
52. Yamauchi H, Yano T, Kato T, Tanaka I, Nakabayashi S, Higashi K, Miyoshi S, Yamada H: Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int J Pharm, 113: 141-148, 1995.
53. Blume G, Cevc G: Liposomes for the sustained drug release in vivo. Biochim Biophys Acta, 1029: 91-97, 1990.
54. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta, 1066: 29-36, 1991.
55. Klibanov AL, Maruyama K, Tochilin VP, Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett, 268: 235-237, 1990.
56. Woodle MC, Lasic DD: Sterically stabilized liposomes. Biochim Biophys Acta, 1113: 171-199, 1992.
57. Woodle MC: Sterically stabilized liposome therapeutics. Adv Drug Deliv Rev, 16: 249-265, 1995.
58. Čeh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD: Stealth® liposomes: from theory to product. Adv Drug Deliv Rev, 24: 165-177, 1997.
59. Coukell AJ, Spencer CM: Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs, 53: 520-538, 1997.
60. Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology, S11: 11-20, 1997.
61. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res, 54: 987-992, 1994.
62. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Bendor CG, Rabello E, Cass Y, Peretz T, Sulkes A, Chisin R, Barenholz Y: Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol, 33: 779-786, 1994.
63. Embree L, Gelmon KA, Lohr A, Mayer LD, Coldman AJ, Cullis PR, Palaitis W, Pilkiewicz F, Hudon NJ, Heggie JR, Goldie JH: Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small cell lung cancer patients. J Pharm Sci, 82: 627-634, 1993.
64. Conley BA, Egorin MJ, Whitacre MY, Carter DC, Zuhowski EG, Vanecho DA: Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol, 33: 107-112, 1993.
65. Woodle MC, Newman MS, Cohen JA: Sterically stabilized liposomes: physical and biological properties. J Drug Target, 2: 397-403, 1994.
66. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol, 36: 55-63, 1996.
67. Gabizon A, Chisin R, Amselem S, Druckmann S, Cohen R, Goren D, Fromer I, Peretz T, Sulkes A, Barenholz Y: Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer, 64: 1125-1132, 1991.
68. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegall T: Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev, 24: 337-344, 1997.
69. Uster PS, Working PK, Vaage J: Pegylated liposomal doxorubicin (Doxil®, Caelyx®) distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm. 162: 77-86, 1998.
70. Harrison M, Tomlinson D, Stewart S: Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol, 13: 914-920, 1995.
71. Wagner D, Kern WV, Kern P: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences. Clin Invest, 72: 417-423, 1994.
72. Northfelt DW: Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. Oncology, S11: 21-32, 1997.
73. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol, 16: 2445-2451, 1998.
74. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ: Randomized comparative trial of pegylated-liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol, 16: 683-691, 1998.
75. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, vonRoenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol, 14: 2353-2364, 1996.
76. Muggia FM: Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs, 54 (suppl 4): 22-29, 1997.
77. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol, 18: 3093-3100, 2000.
78. Muggia FM, Blessing JA, Sorosky J, Reid GC: Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study. J Clin Oncol, 20: 2360-2364, 2002.
79. Muggia FM, Safra T, Groshen S, Jeffers S, Roman L, Tan M, Muderspach L, Burnett A, Formenti S, Morrow CP, Amantea M: Pegylated liposomal doxorubicin: antitumor activity in epithelial ovarian cancer or cancer of peritoneal origin. Oncology, 11, S11: 38-44, 1997.
80. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol, 81: 206-212, 2001.
81. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer, 91: 90-100, 2001.
82. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol, 12: 1408-1414, 1994.
83. Colbern GT, Hiller AJ, Musterer RS, Pegg E, Henderson IC, Working PK: Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J Liposome Res, 9: 523-538, 1999.
84. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer, 86: 72-78, 1999.
85. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest, 19: 424-436, 2001.
86. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol, 15: 3185-3191, 1997.
87. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RCJr, Hortobagyi GN: Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol, 19: 1716-1722, 2001.
88. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP: Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol, 10: 1113-1116, 1999.
89. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58: 2825-2831, 1998.
90. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol, 42: 40-46, 2000.
91. Hubert A, Lyass O, Pode D, Gabizon A: Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs, 11: 123-127, 2000.
92. Caponigro F, Comella P, Budillon A, Bryce J, Avallone A, De Rosa V, Ionna F, Comella G: Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol, 11: 339-342, 2000.
93. Hong RL, Tseng YL, Chang FH: Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol, 11: 349-353, 2000.
94. Uziely B, Jeffers S, Isacson R, Kutsch K, Weitsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor-activity and unique toxicities during two complementary phase 1 studies. J Clin Oncol, 13: 1777-1785, 1995.
95. Nagore E, Insa A, Sanmartin O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol, 1: 225-234, 2000.
96. Alberts DS, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs, 54 (suppl 4): 30-35, 1997.
97. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, Vonroenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer, 75: 2169-2173, 1995.
98. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89: 1037-1047, 2000.
99. Gottlieb JJ, Washenik K, Chachoua A, FriedmanKien A: Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet, 350: 1363-1364, 1997.
100. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG: Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol, 39: 410-416, 1997.
101. Madhavan S, Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst, 87: 1556-1557, 1995.
102. 2. Ann Oncol, 11: 1029-1033, 2000.
103. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using anti-her2 immunoliposomes. J Control Release, 74: 95-113, 2001.
104. Allen TM: Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci, 15: 215-220, 1994.
105. Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L: Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci, 86: 832-839, 1997.
106. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer, 74: 1749-1756, 1996.
107. Forssen E, Willis M: Ligand-targeted liposomes. Adv Drug Deliv Rev, 29: 249-271, 1998.
108. Verhoeyen ME, van der Logt CPE, Beggs TS, Davis PJ: Antibody fragments for controlled delivery of therapeutic agents. Biochem Soc Trans, 23: 1067-1073, 1995.
109. Reddy JA, Low PS: Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst, 15: 587-627, 1998.
110. Vogel K, Wang S, Lee RJ, Chmielewski J, Low PS: Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J Am Chem Soc, 118: 1581-1586, 1996.
111. Bally MB, Harvie P, Wong FMP, Kong S, Wasan EK, Reimer DL: Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev, 38: 291-315, 1999.
112. Stella B, Arpicco S, Peracchia MT, Desmaële D, Hoebeke J, Renoir M, D'Angelo J, Cattel L, Couvreur P: Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci, 89: 1452-1464, 2000.
113. Ceruti M, Crosasso P, Brusa P, Arpicco S, Dosio F, Cattel L: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release, 63: 141-153, 2000.
114. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L: Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release, 63: 19-30, 2000.
115. Gao X, Huang L: Cationic liposome-mediated gene transfer. Gene Ther, 2: 710-722, 1995.
116. Ogihara-Umeda I, Sasaki T, Kojima S, Nishigori H: Optimal radiolabeled liposomes for tumor imaging. J Nucl Med, 37: 326-332, 1996.
117. Woodle MC: 67gallium-labeled liposomes with prolonged circulation: preparation and potential as nuclear imaging agents. Nucl Med Biol, 20: 149-155, 1993.
118. Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK: Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target, 3: 321-340, 1996.
119. Oku N: Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Deliv Rev, 37: 53-61, 1999.
120. Verdonck LF, Lokhorst HM, Roovers DJ, van Heugten HG: Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin. Leuk Res, 22: 249-256, 1998.
121. van Bree C, Krooshoop JJ, Rietbroek RC, Kipp JBA, Bakker PJM: Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res, 56: 563-568, 1996.